-transparent.png){kind=logo}
BACKGROUND Human carcinoembryonic antigen (CEA) is a 180-kd glycoprotein expressed in human colorectal, gastric, pancreatic, breast, and non-small-cell lung carcinomas. Previous studies have demonstrated enhanced immune responses to other antigens presented with vaccinia virus proteins via a recombinant vaccinia virus construct. In addition, we have developed a recombinant CEA-vaccinia virus construct, designated rV(WR)-CEA, and have demonstrated humoral anti-CEA responses in mice after immunization with that virus. OBJECTIVE The goals of this study were (a) to construct a recombinant CEA-vaccinia vaccine in a less virulent vaccinia strain that is potentially safe and effective for treatment of patients whose tumors express CEA and (b) to evaluate the ability of the recombinant CEA-vaccinia vaccine to prevent and reverse tumor growth in mice and to elicit cell-mediated and humoral anti-CEA immune responses. METHODS Using the New York City strain of vaccinia virus, which is used in smallpox vaccination and is more attenuated for humans than rV(WR), we derived a recombinant CEA-vaccinia construct, designated rV(NYC)-CEA. The ability of this construct to induce antitumor immunity was evaluated in mice receiving subcutaneous injections of murine colon adenocarcinoma cells expressing the human CEA gene. RESULTS Administration of rV(NYC)-CEA in mice induced strong anti-CEA antibody responses, as well as CEA-specific cell-mediated responses, including delayed-type hypersensitivity, lymphoproliferative, and cytotoxic responses. Vaccination of mice with the rV(NYC)-CEA rendered them resistant to the growth of subsequently transplanted CEA-expressing tumors. Moreover, when mice were vaccinated 7 days after tumor cell injection, tumor growth was either greatly reduced or eliminated. No toxic effects were observed in any of the mice. CONCLUSIONS These studies demonstrate that antitumor activity can be induced with the use of a recombinant CEA-vaccinia virus construct derived from an attenuated vaccinia strain, and they reveal the range of cell-mediated and humoral responses induced by this recombinant vaccine.
J Kantor, and
K Irvine, and
S Abrams, and
H Kaufman, and
J DiPietro, and
J Schlom
October 1986,
Proceedings of the National Academy of Sciences of the United States of America,
J Kantor, and
K Irvine, and
S Abrams, and
H Kaufman, and
J DiPietro, and
J Schlom
July 1991,
International journal of cancer,
J Kantor, and
K Irvine, and
S Abrams, and
H Kaufman, and
J DiPietro, and
J Schlom
November 1994,
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy,
J Kantor, and
K Irvine, and
S Abrams, and
H Kaufman, and
J DiPietro, and
J Schlom
September 2004,
Human gene therapy,
J Kantor, and
K Irvine, and
S Abrams, and
H Kaufman, and
J DiPietro, and
J Schlom
January 2000,
Clinical cancer research : an official journal of the American Association for Cancer Research,
J Kantor, and
K Irvine, and
S Abrams, and
H Kaufman, and
J DiPietro, and
J Schlom
February 2000,
Clinical lung cancer,
J Kantor, and
K Irvine, and
S Abrams, and
H Kaufman, and
J DiPietro, and
J Schlom
January 1995,
Gene therapy,
J Kantor, and
K Irvine, and
S Abrams, and
H Kaufman, and
J DiPietro, and
J Schlom
April 2006,
Clinical immunology (Orlando, Fla.),
J Kantor, and
K Irvine, and
S Abrams, and
H Kaufman, and
J DiPietro, and
J Schlom
January 1992,
Vaccine,
J Kantor, and
K Irvine, and
S Abrams, and
H Kaufman, and
J DiPietro, and
J Schlom
December 2000,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
